Cerecor (CERC) Scheduled to Post Quarterly Earnings on Monday
Shares of Cerecor (NASDAQ CERC) opened at $4.93 on Monday. The company has a market capitalization of $128.45 and a P/E ratio of 13.32. Cerecor has a 1-year low of $0.34 and a 1-year high of $5.74.
Several research firms have recently commented on CERC. ValuEngine upgraded Cerecor from a “sell” rating to a “hold” rating in a report on Friday, December 1st. TheStreet upgraded Cerecor from an “e+” rating to a “c-” rating in a report on Wednesday, November 8th.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.